Variants in the Dihydropyrimidine Dehydrogenase,Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients
Free accessResearch articleFirst published online June, 2010
Variants in the Dihydropyrimidine Dehydrogenase,Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients
Adverse drug reactions to 5-fluorouracil (5-FU)-based chemotherapy have been reported to be due, in part, to genetic variants of the genes for the drug-related enzymes thymidylate synthase (TS; TYMS gene), methylenetetrahydrofolate reductase (MTHFR gene) and dihydropyrimidine dehydrogenase (DPD; DPYD gene). This study investigated whether selected genetic variants of the TYMS, MTHFR and DPYD genes predict 5-FU-related early toxicity. The prevalence of the genetic variants was determined in 122 colorectal cancer patients and in a reference population of 320 blood donors. Subgroup analysis of 68 of the colorectal cancer patients was carried out to determine the relationship between selected gene variants detected in peripheral mononuclear cells and tolerability during the first or second cycle of 5-FU based treatment. Toxicity was linked to the TYMS 2R/2R variant (relative risk [RR] 1.66; sensitivity 0.37; specificity 0.77) and to the MTHFR c1298 C/C genetic variant (RR 1.77; sensitivity 0.17; specificity 0.91). Patients with the genetic variant IVS14+1 G/A or c1896 C/T in the DPYD gene had a statistically significant increased risk of experiencing toxicity (RR 2 and 6, respectively), both having a high specificity (0.97 and 0.98, respectively) and low sensitivity (0.04 and 0.13, respectively). It is concluded that pre-treatment detection of genetic variants can help to predict early toxicity experienced by patients receiving 5-FU-based chemotherapy.
Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol1998; 16: 3537–3541.
2.
HeidelbergerCChaudhuriNKDannebergP: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature1957; 179: 663–666.
3.
DuschinskyRPlevenEHeidelbergerC: The synthesis of 5-fluoropyrimidines. J Am Chem Soc1957; 79: 4559.
4.
EzzeldinHDiasioR: Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer2004; 4: 181–189.
5.
DiasioRBJohnsonMR: Dihydropyrimidine dehydrogenase; its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res1999; 5: 2672–2673.
6.
TuchmanMStoeckelerJSKiangDT: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Medk1985; 313: 245–249.
7.
DiasioRBBeaversTLCarpenterJT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest1988; 81: 47–51.
8.
GamelinEBoisdron-CelleMDelvaR: Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol1998; 16: 1470–1478.
CiccoliniJMercierCDahanL: Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: Probable implication of dihydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol2006; 58: 272–275.
11.
IchikawaW: Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer2006; 9: 145–155.
12.
MaTZhuZGJiYB: Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2′-deoxyuridine. World J Gastroenterol2004; 10: 172–176.
13.
PullarkatSTStoehlmacherJGhaderiV: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J2001; 1: 65–70.
14.
BertinoJRBanerjeeD: Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time?. Clin Cancer Res2003; 9: 1235–1239.
15.
LecomteTFerrazJMZinzindohouéF: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-flurouracil-based chemotherapy. Clin Cancer Res2004; 10: 5880–5888.
16.
CandelariaMTaja-ChayezbLArce-SalinasC: Genetic determinants of cancer efficacy and toxicity: Practical considerations and perspectives. Anticancer Drugs2005; 16: 923–933.
17.
KawakamiKOmuraKKanchiraE: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res1999; 19: 3949–3952.
18.
KawakamiKWatanabeG: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res2003; 63: 6004–6007.
19.
MandolaMVStoehlmacherJZhangW: A 6 bp polymorphism in thymidylate synthase gene causes message instability and is associated with decreased intratumoural TS mRNA levels. Pharmacogenetics2004; 14: 319–327.
20.
LenzHJZhangWZhahedyS: A 6 basepair deletion in the 3′UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumours. A possible candidate gene for colorectal cancer risk. Proc Am Assoc Cancer Res2002; 43: 660 [abstract].
21.
DolnickBJChengYC: Human thymidylate synthetase. II. Derivatives of pteroylmono- and -polyglutamates as substrates and inhibitors. J Biol Chem1978; 253: 3563–3567.
22.
RadparvarSHoughtonPJHoughtonJA: Effect of polyglutamylation of 5, 10-methylenetetrahydrofolate on the binding of 5-fluoro-2′-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol1989; 38: 335–342.
23.
SohnKJCroxfordRYatesZ: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst2004; 96: 134–144.
24.
CohenVPanet-RaymondVSabbaghianN: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res2003; 9: 1611–1615.
25.
EtienneMCFormentoJLChazalM: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics2004; 14: 785–792.
26.
JakobsenANielsenJNGyldenkerneN: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol2005; 23: 1365–1369.
27.
LuJWGaoCMWuJZ: Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma. Ai Zheng2004; 23: 958–962 [in Chinese].
28.
FrosstPBlomHJMilosR: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet1995; 10: 111–113.
29.
ToffoliGVeronesiABoiocchiM: MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophoshamide, methotrexate, and fluorouracil (CMF). Ann Oncol2000; 11: 373–374.
30.
DanenbergPVDanenbergKD: Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism. Biochemistry1978; 17: 4018–4024.
31.
HeggieGDSommadossiJPCrossDS: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res1987; 47: 2203–2206.
32.
DiasioRB: Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Williston Park)2001; 15 (1 suppl 2): 21–26.
33.
van KuilenburgABHaasjesJRichelDJ: Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res2000; 6: 4705–4712.
34.
SaifMWElfikyADiasioR: Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer2006; 6: 219–223.
35.
van KuilenburgABMullerEWHaasjesJ: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res2001; 7: 1149–1153.
36.
Collie-DuguidESEtienneMCMilanoG: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics2000; 10: 217–223.
37.
van KuilenburgABDobritzschDMeinsmaR: Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J2002; 364: 157–163.
38.
VrekenPvan KuilenburgABMeinsmaR: Dihydropyrimidine dehydrogenase (DPD) deficiency: Identification and expression of missense mutations C29R, R886H and R235W. Hum Genet1997; 101: 333–338.
39.
de GramontAFigerASeymourM: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000; 18: 2938–2947.
40.
ChanskyKBenedettiJMacdonaldJS: Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer2005; 103: 1165–1171.
41.
ChoiJKongKMozaffarTHolcombeRF: Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs2006; 17: 103–105.
GamelinLBoisdron-CelleMMorelA: Oxaliplatin-related neurotoxicity: Interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol2008; 26: 1188–1189.
44.
RudbeckLDissingJ: Rapid, simple alkaline extraction of human genomic DNA from whole blood, buccal epithelial cells, semen and forensic stains for PCR. Biotechniques1998; 25: 588–590.
MarshSCollie-DuguidESLiT: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics1999; 58: 310–312.
47.
VillafrancaEOkruzhnovYDominguezMA: Polymorphism of repeated sequences in the enhancer region of thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol2001; 19: 1779–1786.
48.
EtienneMCLagrangeJLDassonvilleO: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol1994; 12: 2248–2253.
49.
KekuTMillikanRWorleyK: 5, 10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev2002; 11: 1611–1621.
50.
MattisonLKJohnsonMRDiasioRB: A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics2002; 12: 133–144.
51.
GrossEUllrichTSeckK: Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat2003; 22: 498.
52.
SeckKRiemerSKatesR: Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res2005; 11: 5886–5892.
YamaguchiKAraiYKandaY: Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res2001; 92: 337–342.
55.
de GramontABossetJFMilanC: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol1997; 15: 808–815.
56.
DouillardJYCunninghamDRothAD: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet2000; 355: 1041–1047.
57.
GamelinECDanquechin-DorvalEMDumesnilYF: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer1996; 77: 441–451.
58.
van KuilenburgABMeinsmaRvan GennipAH: Pyrimidine degradation defects and severe 5-fluorouracil toxicity. Nucleosides Nucleotides Nucleic Acids2004; 23: 1371–1375.
59.
LabiancaRBerettaGClericiM: Cardiac toxicity of 5-fluorouracil: A study on 1083 patients. Tumori1982; 68: 505–510.
60.
MandolaMVStoehlmacherJMuller-WeeksS: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res2003; 63: 2898–2904.
61.
CapitainOBoisdron-CelleMPoirierAL: The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J2008; 8: 256–267.
62.
SharmaRHoskinsJMRivoryLP: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res2008; 14: 817–825.
63.
ChenJHunterDJStampferMJ: Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomarkers Prev2003; 12: 958–962.
64.
van KuilenburgABVrekenPRivaD: Clinical and biochemical abnormalities in a patient with dihydropyrimidine dehydrogenase deficiency due to homozygosity for the C29R mutation. J Inherit Metab Dis1999; 22: 191–192.
65.
MorelABoisdron-CelleMFeyL: Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem2007; 40: 11–17.
66.
Van KuilenburgABVan LentheHVan GennipAH: Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl1999; 729: 307–314.
67.
PradoCMBaracosVEMcCargarLJ: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res2007; 13: 3264–3268.
68.
SloanJAGoldbergRMSargentDJ: Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol2002; 20: 1491–1498.
69.
ColhounHMMcKeiguePMSmithG Davey: Problems of reporting genetic associations with complex outcomes. Lancet2003; 361: 865–872.
70.
SoongRDiasioRB: Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics2005; 6: 835–847.
71.
VolkJReinkeFvan KuilenburgAB: Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann Oncol2001; 12: 569–571.
72.
BlascoHBoisdron-CelleMBougnouxP: A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol2008; 65: 966–970.
